Business

Announcement on Voluntary Disclosure of National Institute for Health and Care Excellence's Recommendation of Baiyueze (Zanubrutinib Capsules) for Treatment of Adult Patients with Chronic Lymphocytic Leukemia

Announcement on Voluntary Disclosure of National Institute for Health and Care Excellence's Recommendation of Baiyueze (Zanubrutinib Capsules) for Treatment of Adult Patients with Chronic Lymphocytic Leukemia

articleBeone Medicines Ltd. Class AOctober 20, 20234/news/announcement-on-voluntary-disclosure-of-national-institute-for-health-and-care-excellences-recommendation-of-baiyueze-zanubrutinib-capsules-for-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia
Announcement on Voluntary Disclosure of National Institute for Health and Care Excellence's Recommendation of Baiyueze (Zanubrutinib Capsules) for Treatment of Adult Patients with Chronic Lymphocytic Leukemia

About this update from Beone Medicines Ltd. Class A

Announcement on Voluntary Disclosure of National Institute for Health and Care Excellence's Recommendation of Baiyueze (Zanubrutinib Capsules) for Treatment of Adult Patients with Chronic Lymphocytic LeukemiaThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference:" target="_blank">View Attachment

View stock analysis, news, and events for Beone Medicines Ltd. Class A